Sign in to view content

Abicipar Phase 2 MAPLE Trial: Evaluation of All Patients With Post-Injection Inflammation

Tarek S. Hassan, MD, FASRS

Video
Published 2020

Related

Home OCT and Artificial Intelligence in Neovascular AMD
Miguel A. Busquets, MD, FACS
Annual Meeting Talks
2023
Safety and Efficacy of Switching to Biosimilar Ranibizumab in Eyes Initially Treated With Reference Ranibizumab for nAMD, DME, or RVO
Nikhil K Bommakanti, MD
Annual Meeting Talks
2024
Abicipar for nAMD Provides Faster Retinal Fluid Resolution, and Achieved Similar Dryness Through Week 104 With Fewer Injections
Nancy M. Holekamp, MD, FASRS
Annual Meeting Talks
2020

Category: AMD-Neovascular

See more